Cas:93-05-0 N,N-Diethyl-p-phenylenediamine manufacturer & supplier

Chemical Name:N,N-Diethyl-p-phenylenediamine

CAS.NO:93-05-0

Synonyms:EINECS 202-214-1;4-N,4-N-diethylbenzene-1,4-diamine;MFCD00007861

Molecular Formula:C₁₀H₁₆N₂

Molecular Weight:164.24700

HS Code:29215190

Physical and Chemical Properties:

Melting point:19-21 °C(lit.)

Boiling point:115-116 °C5 mm Hg(lit.)

Density:0.988 g/mL at 25 °C(lit.)

Index of Refraction:n20/D 1.571(lit.)

PSA:29.26000

Exact Mass:164.13100

LogP:2.69620

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:UN 2922 8/PG 2

Packing Group:III

Contact us for information like EINECS 202-214-1 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00007861 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-N,4-N-diethylbenzene-1,4-diamine Use and application,EINECS 202-214-1 technical grade,usp/ep/jp grade.

Related News: An effective treatment for Alzheimer��s, which is estimated in 60%-70% of around 50 million dementia cases worldwide, could become one of the best-selling drugs globally. N,N-Diethyl-p-phenylenediamine manufacturer At the same time, experts said that API companies need to increase investment in environmental protection, carry out industrial upgrades, improve processes, improve pollution treatment capabilities, and then achieve sustainable development in the future, and seize structural opportunities. N,N-Diethyl-p-phenylenediamine supplier The measure starts on February 4, according to South Korean Prime Minister Chung Sye-kyun. N,N-Diethyl-p-phenylenediamine vendor At the same time, experts said that API companies need to increase investment in environmental protection, carry out industrial upgrades, improve processes, improve pollution treatment capabilities, and then achieve sustainable development in the future, and seize structural opportunities. N,N-Diethyl-p-phenylenediamine factory Darzalex does have another regimen approved for the same myeloma population. Darzalex combined with Takeda’s Velcade, melphalan and prednisone (VMP) reduced the risk of death by 40% in the phase 3 ALCYONE trial. But disease progression had already occurred in half of patients on the Darzalex-VMP combo after about three years of follow-up, a much shorter period than the five-year mark the Darzalex-Rd regimen is approaching.